Also trades as: IPSEY (OTC) · $vol 0M · IPSEF (OTC) · $vol 0M

€139.60 ($157.15)

-1.00 (-0.71%)

Weekly Expected Move ±3.8%

€129 €134 €140 €145 €150

PAR · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 32 · €11.5B mcap · 30M float · 0.390% daily turnover

Revenue

$3.7B +2.8% ▲

5Y CAGR: +6.5%

Gross Profit

$2.6B -12.2% ▼

5Y CAGR: +3.4%

Operating Income

$746M +50.3% ▲

5Y CAGR: -0.3%

Net Income

$444M +28.5% ▲

5Y CAGR: -4.1%

EPS (Diluted)

$5.32 +28.2% ▲

5Y CAGR: -4.1%

EBITDA

$1.1B -5.1% ▼

5Y CAGR: +6.8%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$2.7B	$3.2B	$3.3B	$3.6B	$3.7B
YoY Growth	+2.3%	+14.8%	+4.8%	+8.1%	+2.8%
Cost of Revenue	$439M	$528M	$571M	$619M	$1.1B
Gross Profit	$2.3B	$2.6B	$2.7B	$3.0B	$2.6B
Gross Margin	84.0%	83.3%	82.7%	82.7%	70.6%
R&D Expenses	$424M	$445M	$619M	$687M	$0
SG&A Expenses	$916M	$1.0B	$1.1B	$1.2B	$0
Operating Expenses	$1.5B	$1.9B	$1.9B	$2.5B	$1.8B
Operating Income	$886M	$944M	$816M	$497M	$746M
Operating Margin	32.2%	29.9%	24.7%	13.9%	20.3%
Interest Expense	$24M	$24M	$19M	$24M	$36M
Income Before Tax	$790M	$704M	$756M	$432M	$578M
Tax Expense	$158M	$112M	$136M	$75M	$134M
Net Income	$647M	$649M	$644M	$346M	$444M
Net Margin	23.5%	20.5%	19.5%	9.7%	12.1%
EPS (Diluted)	$7.57	$7.14	$7.73	$4.15	$5.32
EBITDA	$1.1B	$1.1B	$1.1B	$1.2B	$1.1B
Shares Outstanding	83M	83M	83M	83M	84M

Line Item	FY2022 Q4	FY2023 Q2	FY2023 Q4	FY2024 Q2	FY2024 Q4	FY2025 Q2	FY2025 Q4	FY2026 Q2
Revenue	$1.7B	$1.6B	$1.6B	$1.8B	$1.8B	$1.8B	$1.9B	$2.2B
Cost of Revenue	$286M	$270M	$301M	$317M	$302M	$325M	$756M	$558M
Gross Profit	$1.4B	$1.4B	$1.3B	$1.4B	$1.5B	$1.5B	$1.1B	$1.6B
Gross Margin	82.8%	83.4%	81.1%	81.9%	83.4%	82.1%	59.3%	74.5%
R&D Expenses	$238M	$290M	$329M	$323M	$363M	$365M	$389M	$402M
SG&A Expenses	$552M	$553M	$582M	$575M	$599M	$607M	$557M	$608M
Operating Expenses	$1.2B	$1.1B	$819M	$1.1B	$1.3B	$854M	$994M	$901M
Operating Income	$439M	$380M	$471M	$318M	$179M	$640M	$488M	$731M
Operating Margin	26.4%	23.4%	29.6%	18.1%	9.8%	35.2%	26.3%	33.4%
Interest Expense	$12M	$15M	$11M	$11M	$12M	$16M	$20M	$21M
Income Before Tax	$214M	$251M	$500M	$290M	$143M	$425M	$153M	$548M
Tax Expense	$4M	$56M	$80M	$47M	$28M	$90M	$44M	$145M
Net Income	$211M	$195M	$449M	$232M	$114M	$334M	$110M	$403M
Net Margin	12.7%	12.0%	28.2%	13.2%	6.2%	18.4%	5.9%	18.4%
EPS (Diluted)	$2.54	$2.35	$5.38	$2.78	$1.37	$4.00	$1.32	$4.86
EBITDA	$520M	$432M	$672M	$482M	$710M	$637M	$466M	$1.0B
Shares Outstanding	83M	83M	84M	83M	83M	84M	82M	83M

IPN.PA PAR